Generation and characterization of mAb 61H9 against junctional adhesion molecule-a with potent antitumor activity
Junctional adhesion molecule-A (JAM-A) is an adhesion molecule that exists on the surface of certain types of cells, including white blood cells, endothelial cells, and dendritic cells. In this study, the cDNA sequences of JAM-A-Fc were chemically synthesized with optimization for mammalian expressi...
Saved in:
Published in | PeerJ (San Francisco, CA) Vol. 12; p. e17088 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
PeerJ Inc
14.03.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Junctional adhesion molecule-A (JAM-A) is an adhesion molecule that exists on the surface of certain types of cells, including white blood cells, endothelial cells, and dendritic cells. In this study, the cDNA sequences of JAM-A-Fc were chemically synthesized with optimization for mammalian expression. Afterward, we analyzed JAM-A protein expression through transient transfection in HEK293 cell lines. Mice were immunized with JAM-A-Fc protein, and hybridoma was prepared by fusing myeloma cells and mouse spleen cells. Antibodies were purified from the hybridoma supernatant and four monoclonal strains were obtained and numbered 61H9, 70E5, 71A8, and 74H3
enzyme-linked immunosorbent assay screening. Immunofluorescence staining assay showed 61H9 was the most suitable cell line for mAb production due to its fluorescence signal being the strongest. Flow cytometric analysis proved that 61H9 possessed high affinity. Moreover, antagonism of JAM-A mAb could attenuate the proliferative, migrative, and invasive abilities of ESCC cells and significantly inhibit tumor growth in mice. By examining hematoxylin-eosin staining mice tumor tissues, we found inflammatory cells infiltrated lightly in the anti-JAM-A group. The expression of BCL-2 and IκBα in the anti-JAM-A group were decreased in mice tumor tissues compared to the control group. Ultimately, a method for preparing high-yield JAM-A-Fc protein was created and a high affinity mAb against JAM-A with an antitumor effect was prepared. |
---|---|
AbstractList | Junctional adhesion molecule-A (JAM-A) is an adhesion molecule that exists on the surface of certain types of cells, including white blood cells, endothelial cells, and dendritic cells. In this study, the cDNA sequences of JAM-A-Fc were chemically synthesized with optimization for mammalian expression. Afterward, we analyzed JAM-A protein expression through transient transfection in HEK293 cell lines. Mice were immunized with JAM-A-Fc protein, and hybridoma was prepared by fusing myeloma cells and mouse spleen cells. Antibodies were purified from the hybridoma supernatant and four monoclonal strains were obtained and numbered 61H9, 70E5, 71A8, and 74H3
via
enzyme-linked immunosorbent assay screening. Immunofluorescence staining assay showed 61H9 was the most suitable cell line for mAb production due to its fluorescence signal being the strongest. Flow cytometric analysis proved that 61H9 possessed high affinity. Moreover, antagonism of JAM-A mAb could attenuate the proliferative, migrative, and invasive abilities of ESCC cells and significantly inhibit tumor growth in mice. By examining hematoxylin-eosin staining mice tumor tissues, we found inflammatory cells infiltrated lightly in the anti-JAM-A group. The expression of BCL-2 and IκBα in the anti-JAM-A group were decreased in mice tumor tissues compared to the control group. Ultimately, a method for preparing high-yield JAM-A-Fc protein was created and a high affinity mAb against JAM-A with an antitumor effect was prepared. Junctional adhesion molecule-A (JAM-A) is an adhesion molecule that exists on the surface of certain types of cells, including white blood cells, endothelial cells, and dendritic cells. In this study, the cDNA sequences of JAM-A-Fc were chemically synthesized with optimization for mammalian expression. Afterward, we analyzed JAM-A protein expression through transient transfection in HEK293 cell lines. Mice were immunized with JAM-A-Fc protein, and hybridoma was prepared by fusing myeloma cells and mouse spleen cells. Antibodies were purified from the hybridoma supernatant and four monoclonal strains were obtained and numbered 61H9, 70E5, 71A8, and 74H3 enzyme-linked immunosorbent assay screening. Immunofluorescence staining assay showed 61H9 was the most suitable cell line for mAb production due to its fluorescence signal being the strongest. Flow cytometric analysis proved that 61H9 possessed high affinity. Moreover, antagonism of JAM-A mAb could attenuate the proliferative, migrative, and invasive abilities of ESCC cells and significantly inhibit tumor growth in mice. By examining hematoxylin-eosin staining mice tumor tissues, we found inflammatory cells infiltrated lightly in the anti-JAM-A group. The expression of BCL-2 and IκBα in the anti-JAM-A group were decreased in mice tumor tissues compared to the control group. Ultimately, a method for preparing high-yield JAM-A-Fc protein was created and a high affinity mAb against JAM-A with an antitumor effect was prepared. Junctional adhesion molecule-A (JAM-A) is an adhesion molecule that exists on the surface of certain types of cells, including white blood cells, endothelial cells, and dendritic cells. In this study, the cDNA sequences of JAM-A-Fc were chemically synthesized with optimization for mammalian expression. Afterward, we analyzed JAM-A protein expression through transient transfection in HEK293 cell lines. Mice were immunized with JAM-A-Fc protein, and hybridoma was prepared by fusing myeloma cells and mouse spleen cells. Antibodies were purified from the hybridoma supernatant and four monoclonal strains were obtained and numbered 61H9, 70E5, 71A8, and 74H3 via enzyme-linked immunosorbent assay screening. Immunofluorescence staining assay showed 61H9 was the most suitable cell line for mAb production due to its fluorescence signal being the strongest. Flow cytometric analysis proved that 61H9 possessed high affinity. Moreover, antagonism of JAM-A mAb could attenuate the proliferative, migrative, and invasive abilities of ESCC cells and significantly inhibit tumor growth in mice. By examining hematoxylin-eosin staining mice tumor tissues, we found inflammatory cells infiltrated lightly in the anti-JAM-A group. The expression of BCL-2 and IκBα in the anti-JAM-A group were decreased in mice tumor tissues compared to the control group. Ultimately, a method for preparing high-yield JAM-A-Fc protein was created and a high affinity mAb against JAM-A with an antitumor effect was prepared. |
ArticleNumber | e17088 |
Author | Wang, Zhenling Yang, Hang Shen, Yunlong Yang, Jinliang Liu, Kang Xiong, Rong Song, Guiqin |
Author_xml | – sequence: 1 givenname: Kang orcidid: 0000-0002-4640-0849 surname: Liu fullname: Liu, Kang organization: Institute of Tissue Engineering and Stem Cells, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, China – sequence: 2 givenname: Hang surname: Yang fullname: Yang, Hang organization: Institute of Tissue Engineering and Stem Cells, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, China – sequence: 3 givenname: Rong surname: Xiong fullname: Xiong, Rong organization: Institute of Tissue Engineering and Stem Cells, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, China – sequence: 4 givenname: Yunlong surname: Shen fullname: Shen, Yunlong organization: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, Sichuan, China – sequence: 5 givenname: Guiqin orcidid: 0000-0002-8068-4742 surname: Song fullname: Song, Guiqin organization: School of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China – sequence: 6 givenname: Jinliang surname: Yang fullname: Yang, Jinliang organization: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, Sichuan, China – sequence: 7 givenname: Zhenling surname: Wang fullname: Wang, Zhenling organization: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, Sichuan, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38495763$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkc1r3DAQxU1JaT6aU-9Fx0JxKllayTqVENokEOilPYuxPN7VYksbSU5J__rKu0lIdBnx5vGbGd5pdeSDx6r6xOiFUkx92yHG7QVTtG3fVScNk6pu-UofvfofV-cpbWl5bSNpyz9Ux7wVeqUkP6nur9FjhOyCJ-B7YjcQwWaM7t9BDAOZLjsi2Y0msAbnUybb2dulCSOBfoNp8U1hRDuPWAP56_KG7EJGnwszuzxPIZJCdQ8uP36s3g8wJjx_qmfVn58_fl_d1He_rm-vLu9qK6jMteYMuq5DKVupLVCrBDJJpaKyV4pyzRrNByrbrhsApVaiiBxKv1Oi3MnPqtsDtw-wNbvoJoiPJoAzeyHEtYGYnR3R0MYyLXshoEwZJNO8GXjPqQY-dKxvC-v7gbWbuwl7Wy6LML6Bvu14tzHr8GAY1UJIvmzz5YkQw_2MKZvJJYvjCB7DnEyjy-YrKVaL9evBamNIKeLwModRs4Ru9qGbfejF_fn1ai_e54j5f0zmqyY |
Cites_doi | 10.1371/journal.pone.0079173 10.1186/s13058-018-1064-1 10.3390/cancers13061286 10.2217/fon-2019-0024 10.1016/j.annonc.2021.02.004 10.3978/j.issn.2305-5839.2015.08.01 10.1038/leu.2017.287 10.1161/CIRCRESAHA.120.316742 10.1007/s00018-017-2729-0 10.1038/onc.2012.276 10.1128/JVI.80.3.1261-1270.2006 10.1007/s13577-022-00806-1 10.1371/journal.pone.0021242 10.1038/ajg.2017.155 10.1038/nri.2017.52 10.1016/S2468-1253(20)30007-8 10.1039/C5AN01323B 10.2147/jpr.S33408 10.3322/caac.21492 10.1007/s10549-019-05471-x 10.1053/j.gastro.2021.10.017 10.2174/0929867327666201111142307 10.1016/S1470-2045(20)30169-8 10.1016/S0140-6736(17)31827-5 10.1080/14728222.2022.2036718 10.1200/jco.20.01888 10.1161/01.ATV.0000157154.14474.3b 10.3390/cancers12123614 10.1007/s00432-021-03659-7 10.1016/S1470-2045(14)70442-5 10.1177/1010428317691000 10.1002/ijc.24498 10.1038/s41417-022-00507-9 10.1093/emboj/20.14.3738 10.1038/s41467-023-37440-w 10.1093/carcin/bgu230 10.1007/s10147-020-01652-7 10.3324/haematol.2019.239913 10.2217/fon-2021-0021 10.1083/jcb.142.1.117 10.1038/labinvest.3700671 10.1242/jcs.114.3.539 10.1182/blood-2010-10-299487 10.1634/theoncologist.2018-0143 10.1038/s41575-021-00419-3 |
ContentType | Journal Article |
Copyright | 2024 Liu et al. 2024 Liu et al. 2024 Liu et al. |
Copyright_xml | – notice: 2024 Liu et al. – notice: 2024 Liu et al. 2024 Liu et al. |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.7717/peerj.17088 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2167-8359 |
EndPage | e17088 |
ExternalDocumentID | oai_doaj_org_article_02c196d44ac74f61932f3d309a3fb1d8 10_7717_peerj_17088 38495763 |
Genre | Journal Article |
GrantInformation_xml | – fundername: National Natural Science Foundation grantid: 82203851 – fundername: Nanchong Science and Technology Program grantid: 22SXQT0336,20SXQT0328 – fundername: Sichuan Science and Technology Program grantid: 2023NSFSC0731, 2023YFSY0045 |
GroupedDBID | 3V. 53G 5VS 88I 8FE 8FH AAFWJ ABUWG ADBBV ADRAZ AENEX AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU DIK DWQXO ECGQY GNUQQ GROUPED_DOAJ GX1 HCIFZ HYE IAO IEA IHR IHW ITC KQ8 LK8 M2P M48 M7P M~E NPM OK1 PIMPY PQQKQ PROAC RPM W2D YAO AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c406t-931abbbe66869ca0c74e1606706d770391293f068bbfae69747033a670b742603 |
IEDL.DBID | RPM |
ISSN | 2167-8359 |
IngestDate | Thu Jul 04 21:10:03 EDT 2024 Tue Apr 09 21:55:26 EDT 2024 Fri Apr 12 14:29:48 EDT 2024 Fri Aug 23 00:48:20 EDT 2024 Thu May 23 23:26:35 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Anti-JAM-A Hybridoma Monoclonal antibody Junctional adhesion molecule-A Esophageal cancer |
Language | English |
License | 2024 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c406t-931abbbe66869ca0c74e1606706d770391293f068bbfae69747033a670b742603 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-4640-0849 0000-0002-8068-4742 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944630/ |
PMID | 38495763 |
PQID | 2967056450 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_02c196d44ac74f61932f3d309a3fb1d8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10944630 proquest_miscellaneous_2967056450 crossref_primary_10_7717_peerj_17088 pubmed_primary_38495763 |
PublicationCentury | 2000 |
PublicationDate | 2024-03-14 |
PublicationDateYYYYMMDD | 2024-03-14 |
PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-14 day: 14 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: San Diego, USA |
PublicationTitle | PeerJ (San Francisco, CA) |
PublicationTitleAlternate | PeerJ |
PublicationYear | 2024 |
Publisher | PeerJ Inc |
Publisher_xml | – name: PeerJ Inc |
References | Steinbacher (10.7717/peerj.17088/ref-37) 2018; 75 Danthi (10.7717/peerj.17088/ref-6) 2006; 80 Salem (10.7717/peerj.17088/ref-31) 2018; 23 Kojima (10.7717/peerj.17088/ref-15) 2020; 38 Zhang (10.7717/peerj.17088/ref-43) 2013; 8 Solimando (10.7717/peerj.17088/ref-36) 2021; 106 Thrift (10.7717/peerj.17088/ref-40) 2021; 18 Bednarek (10.7717/peerj.17088/ref-2) 2020; 179 Rajkumar (10.7717/peerj.17088/ref-27) 2014; 15 Solimando (10.7717/peerj.17088/ref-35) 2018; 32 Leech (10.7717/peerj.17088/ref-17) 2015; 3 Martìn-Padura (10.7717/peerj.17088/ref-20) 1998; 142 Rogers (10.7717/peerj.17088/ref-30) 2022; 26 Zhang (10.7717/peerj.17088/ref-44) 2022; 148 Collaborators (10.7717/peerj.17088/ref-5) 2020; 5 Jing (10.7717/peerj.17088/ref-12) 2019; 15 Peery (10.7717/peerj.17088/ref-26) 2022; 162 Kang (10.7717/peerj.17088/ref-14) 2017; 390 Nakatani (10.7717/peerj.17088/ref-24) 2020; 25 Xiong (10.7717/peerj.17088/ref-42) 2023; 36 Schellerer (10.7717/peerj.17088/ref-32) 2007; 87 Murakami (10.7717/peerj.17088/ref-22) 2011; 6 Kakogiannos (10.7717/peerj.17088/ref-13) 2020; 127 Ishigaki (10.7717/peerj.17088/ref-10) 2016; 141 Suhail (10.7717/peerj.17088/ref-38) 2021; 28 Janjigian (10.7717/peerj.17088/ref-11) 2020; 21 Zhao (10.7717/peerj.17088/ref-45) 2017; 39 Arnold (10.7717/peerj.17088/ref-1) 2017; 112 Brennan (10.7717/peerj.17088/ref-4) 2013; 32 Ebnet (10.7717/peerj.17088/ref-7) 2001; 20 Han (10.7717/peerj.17088/ref-8) 2021; 17 Naik (10.7717/peerj.17088/ref-23) 2001; 114 Harryvan (10.7717/peerj.17088/ref-9) 2022; 29 Kumar (10.7717/peerj.17088/ref-16) 2012; 5 Li (10.7717/peerj.17088/ref-19) 2023; 14 Bray (10.7717/peerj.17088/ref-3) 2018; 68 Rajkumar (10.7717/peerj.17088/ref-28) 2011; 117 Leech (10.7717/peerj.17088/ref-18) 2018; 20 Sun (10.7717/peerj.17088/ref-39) 2017; 17 McSherry (10.7717/peerj.17088/ref-21) 2009; 125 Smyth (10.7717/peerj.17088/ref-34) 2021; 32 Simoni (10.7717/peerj.17088/ref-33) 2020; 12 Tian (10.7717/peerj.17088/ref-41) 2015; 36 Ostermann (10.7717/peerj.17088/ref-25) 2005; 25 Richards (10.7717/peerj.17088/ref-29) 2021; 13 |
References_xml | – volume: 8 start-page: e79173 issue: 11 year: 2013 ident: 10.7717/peerj.17088/ref-43 article-title: Overexpression of JAM-A in non-small cell lung cancer correlates with tumor progression publication-title: PLOS ONE doi: 10.1371/journal.pone.0079173 contributor: fullname: Zhang – volume: 20 start-page: 140 issue: 1 year: 2018 ident: 10.7717/peerj.17088/ref-18 article-title: Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings publication-title: Breast Cancer Research doi: 10.1186/s13058-018-1064-1 contributor: fullname: Leech – volume: 13 start-page: 1286 issue: 6 year: 2021 ident: 10.7717/peerj.17088/ref-29 article-title: Development of a novel weighted ranking method for immunohistochemical quantification of a heterogeneously expressed protein in gastro-esophageal cancers publication-title: Cancers doi: 10.3390/cancers13061286 contributor: fullname: Richards – volume: 15 start-page: 2413 issue: 20 year: 2019 ident: 10.7717/peerj.17088/ref-12 article-title: Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis publication-title: Future Oncology doi: 10.2217/fon-2019-0024 contributor: fullname: Jing – volume: 32 start-page: 590 issue: 5 year: 2021 ident: 10.7717/peerj.17088/ref-34 article-title: Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy publication-title: Annals of Oncology doi: 10.1016/j.annonc.2021.02.004 contributor: fullname: Smyth – volume: 3 start-page: 184 year: 2015 ident: 10.7717/peerj.17088/ref-17 article-title: Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis publication-title: Annals of Translational Medicine doi: 10.3978/j.issn.2305-5839.2015.08.01 contributor: fullname: Leech – volume: 32 start-page: 736 issue: 3 year: 2018 ident: 10.7717/peerj.17088/ref-35 article-title: JAM-A as a prognostic factor and new therapeutic target in multiple myeloma publication-title: Leukemia doi: 10.1038/leu.2017.287 contributor: fullname: Solimando – volume: 127 start-page: 1056 issue: 8 year: 2020 ident: 10.7717/peerj.17088/ref-13 article-title: JAM-A Acts via C/EBP-α to promote Claudin-5 expression and enhance endothelial barrier function publication-title: Circulation Research doi: 10.1161/CIRCRESAHA.120.316742 contributor: fullname: Kakogiannos – volume: 75 start-page: 1393 issue: 8 year: 2018 ident: 10.7717/peerj.17088/ref-37 article-title: Junctional adhesion molecule-a: functional diversity through molecular promiscuity publication-title: Cellular and Molecular Life Sciences doi: 10.1007/s00018-017-2729-0 contributor: fullname: Steinbacher – volume: 32 start-page: 2799 issue: 22 year: 2013 ident: 10.7717/peerj.17088/ref-4 article-title: Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling publication-title: Oncogene doi: 10.1038/onc.2012.276 contributor: fullname: Brennan – volume: 80 start-page: 1261 issue: 3 year: 2006 ident: 10.7717/peerj.17088/ref-6 article-title: JAM-A-independent, antibody-mediated uptake of reovirus into cells leads to apoptosis publication-title: Journal of Virology doi: 10.1128/JVI.80.3.1261-1270.2006 contributor: fullname: Danthi – volume: 36 start-page: 244 issue: 1 year: 2023 ident: 10.7717/peerj.17088/ref-42 article-title: HOXD11 upregulates JAM-A and exerts oncogenic properties via NF-κB signaling pathway in esophageal squamous cell carcinoma publication-title: Human Cell doi: 10.1007/s13577-022-00806-1 contributor: fullname: Xiong – volume: 6 start-page: e21242 issue: 6 year: 2011 ident: 10.7717/peerj.17088/ref-22 article-title: Abrogation of junctional adhesion molecule-a expression induces cell apoptosis and reduces breast cancer progression publication-title: PLOS ONE doi: 10.1371/journal.pone.0021242 contributor: fullname: Murakami – volume: 112 start-page: 1247 issue: 8 year: 2017 ident: 10.7717/peerj.17088/ref-1 article-title: Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030 publication-title: The American Journal of Gastroenterology doi: 10.1038/ajg.2017.155 contributor: fullname: Arnold – volume: 17 start-page: 545 issue: 9 year: 2017 ident: 10.7717/peerj.17088/ref-39 article-title: The non-canonical NF-κB pathway in immunity and inflammation publication-title: Nature Reviews Immunology doi: 10.1038/nri.2017.52 contributor: fullname: Sun – volume: 5 start-page: 582 issue: 6 year: 2020 ident: 10.7717/peerj.17088/ref-5 article-title: The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 publication-title: The Lancet Gastroenterology & Hepatology doi: 10.1016/S2468-1253(20)30007-8 contributor: fullname: Collaborators – volume: 141 start-page: 1027 issue: 3 year: 2016 ident: 10.7717/peerj.17088/ref-10 article-title: Diagnosis of early-stage esophageal cancer by Raman spectroscopy and chemometric techniques publication-title: The Analyst doi: 10.1039/C5AN01323B contributor: fullname: Ishigaki – volume: 5 start-page: 279 year: 2012 ident: 10.7717/peerj.17088/ref-16 article-title: NGF-the TrkA to successful pain treatment publication-title: Journal of Pain Research doi: 10.2147/jpr.S33408 contributor: fullname: Kumar – volume: 68 start-page: 394 issue: 6 year: 2018 ident: 10.7717/peerj.17088/ref-3 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA: A Cancer Journal for Clinicians doi: 10.3322/caac.21492 contributor: fullname: Bray – volume: 179 start-page: 325 issue: 2 year: 2020 ident: 10.7717/peerj.17088/ref-2 article-title: Functional inhibition of F11 receptor (F11R/junctional adhesion molecule-A/JAM-A) activity by a F11R-derived peptide in breast cancer and its microenvironment publication-title: Breast Cancer Research and Treatment doi: 10.1007/s10549-019-05471-x contributor: fullname: Bednarek – volume: 162 start-page: 621 issue: 2 year: 2022 ident: 10.7717/peerj.17088/ref-26 article-title: Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021 publication-title: Gastroenterology doi: 10.1053/j.gastro.2021.10.017 contributor: fullname: Peery – volume: 28 start-page: 4117 issue: 21 year: 2021 ident: 10.7717/peerj.17088/ref-38 article-title: A critical transcription factor NF-κB as a cancer therapeutic target and its inhibitors as cancer treatment options publication-title: Current Medicinal Chemistry doi: 10.2174/0929867327666201111142307 contributor: fullname: Suhail – volume: 21 start-page: 821 issue: 6 year: 2020 ident: 10.7717/peerj.17088/ref-11 article-title: First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial publication-title: The Lancet Oncology doi: 10.1016/S1470-2045(20)30169-8 contributor: fullname: Janjigian – volume: 390 start-page: 2461 issue: 10111 year: 2017 ident: 10.7717/peerj.17088/ref-14 article-title: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: The Lancet doi: 10.1016/S0140-6736(17)31827-5 contributor: fullname: Kang – volume: 26 start-page: 107 issue: 2 year: 2022 ident: 10.7717/peerj.17088/ref-30 article-title: Esophageal cancer: emerging therapeutics publication-title: Expert Opinion on Therapeutic Targets doi: 10.1080/14728222.2022.2036718 contributor: fullname: Rogers – volume: 38 start-page: 4138 year: 2020 ident: 10.7717/peerj.17088/ref-15 article-title: Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer publication-title: Journal of Clinical Oncology doi: 10.1200/jco.20.01888 contributor: fullname: Kojima – volume: 25 start-page: 729 issue: 4 year: 2005 ident: 10.7717/peerj.17088/ref-25 article-title: Involvement of JAM-A in mononuclear cell recruitment on inflamed or atherosclerotic endothelium: inhibition by soluble JAM-A publication-title: Arteriosclerosis, Thrombosis, and Vascular Biology doi: 10.1161/01.ATV.0000157154.14474.3b contributor: fullname: Ostermann – volume: 12 start-page: 3614 issue: 12 year: 2020 ident: 10.7717/peerj.17088/ref-33 article-title: Long-Term outcomes of induction chemotherapy followed by chemo-radiotherapy as intensive neoadjuvant protocol in patients with esophageal cancer publication-title: Cancers doi: 10.3390/cancers12123614 contributor: fullname: Simoni – volume: 148 start-page: 943 issue: 4 year: 2022 ident: 10.7717/peerj.17088/ref-44 article-title: Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China publication-title: Journal of Cancer Research and Clinical Oncology doi: 10.1007/s00432-021-03659-7 contributor: fullname: Zhang – volume: 15 start-page: e538 issue: 12 year: 2014 ident: 10.7717/peerj.17088/ref-27 article-title: International myeloma working group updated criteria for the diagnosis of multiple myeloma publication-title: Lancet Oncology doi: 10.1016/S1470-2045(14)70442-5 contributor: fullname: Rajkumar – volume: 39 start-page: 1010428317691000 issue: 2 year: 2017 ident: 10.7717/peerj.17088/ref-45 article-title: Overexpression of junctional adhesion molecule-A and EphB2 predicts poor survival in lung adenocarcinoma patients publication-title: Tumour Biology doi: 10.1177/1010428317691000 contributor: fullname: Zhao – volume: 125 start-page: 1343 issue: 6 year: 2009 ident: 10.7717/peerj.17088/ref-21 article-title: JAM-A expression positively correlates with poor prognosis in breast cancer patients publication-title: International Journal of Cancer doi: 10.1002/ijc.24498 contributor: fullname: McSherry – volume: 29 start-page: 1918 issue: 12 year: 2022 ident: 10.7717/peerj.17088/ref-9 article-title: Gastrointestinal cancer-associated fibroblasts expressing junctional adhesion molecule-a are amenable to infection by oncolytic reovirus publication-title: Cancer Gene Therapy doi: 10.1038/s41417-022-00507-9 contributor: fullname: Harryvan – volume: 20 start-page: 3738 issue: 14 year: 2001 ident: 10.7717/peerj.17088/ref-7 article-title: The cell polarity protein ASIP/PAR-3 directly associates with junctional adhesion molecule (JAM) publication-title: The EMBO Journal doi: 10.1093/emboj/20.14.3738 contributor: fullname: Ebnet – volume: 14 start-page: 1666 issue: 1 year: 2023 ident: 10.7717/peerj.17088/ref-19 article-title: Integrative proteogenomic characterization of early esophageal cancer publication-title: Nature Communications doi: 10.1038/s41467-023-37440-w contributor: fullname: Li – volume: 36 start-page: 41 issue: 1 year: 2015 ident: 10.7717/peerj.17088/ref-41 article-title: Junctional adhesion molecule-A, an epithelial-mesenchymal transition inducer, correlates with metastasis and poor prognosis in human nasopharyngeal cancer publication-title: Carcinogenesis doi: 10.1093/carcin/bgu230 contributor: fullname: Tian – volume: 25 start-page: 1098 issue: 6 year: 2020 ident: 10.7717/peerj.17088/ref-24 article-title: Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer publication-title: International Journal of Clinical Oncology doi: 10.1007/s10147-020-01652-7 contributor: fullname: Nakatani – volume: 106 start-page: 1943 issue: 7 year: 2021 ident: 10.7717/peerj.17088/ref-36 article-title: Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression publication-title: Haematologica doi: 10.3324/haematol.2019.239913 contributor: fullname: Solimando – volume: 17 start-page: 2257 issue: 17 year: 2021 ident: 10.7717/peerj.17088/ref-8 article-title: Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis publication-title: Future Oncology doi: 10.2217/fon-2021-0021 contributor: fullname: Han – volume: 142 start-page: 117 issue: 1 year: 1998 ident: 10.7717/peerj.17088/ref-20 article-title: Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration publication-title: The Journal of Cell Biology doi: 10.1083/jcb.142.1.117 contributor: fullname: Martìn-Padura – volume: 87 start-page: 1159 issue: 11 year: 2007 ident: 10.7717/peerj.17088/ref-32 article-title: Endothelial cells of human colorectal cancer and healthy colon reveal phenotypic differences in culture publication-title: Laboratory Investigation doi: 10.1038/labinvest.3700671 contributor: fullname: Schellerer – volume: 114 start-page: 539 issue: 3 year: 2001 ident: 10.7717/peerj.17088/ref-23 article-title: Characterization and chromosomal localization of JAM-1, a platelet receptor for a stimulatory monoclonal antibody publication-title: Journal of Cell Science doi: 10.1242/jcs.114.3.539 contributor: fullname: Naik – volume: 117 start-page: 4691 issue: 18 year: 2011 ident: 10.7717/peerj.17088/ref-28 article-title: Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 publication-title: Blood doi: 10.1182/blood-2010-10-299487 contributor: fullname: Rajkumar – volume: 23 start-page: 1319 issue: 11 year: 2018 ident: 10.7717/peerj.17088/ref-31 article-title: Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma publication-title: The Oncologist doi: 10.1634/theoncologist.2018-0143 contributor: fullname: Salem – volume: 18 start-page: 432 issue: 6 year: 2021 ident: 10.7717/peerj.17088/ref-40 article-title: Global burden and epidemiology of Barrett oesophagus and oesophageal cancer publication-title: Nature Reviews Gastroenterology & Hepatology doi: 10.1038/s41575-021-00419-3 contributor: fullname: Thrift |
SSID | ssj0000826083 |
Score | 2.356321 |
Snippet | Junctional adhesion molecule-A (JAM-A) is an adhesion molecule that exists on the surface of certain types of cells, including white blood cells, endothelial... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | e17088 |
SubjectTerms | Anti-JAM-A Biotechnology Cell Biology Esophageal cancer Hybridoma Immunology Junctional adhesion molecule-A Monoclonal antibody Oncology |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT-MwELYQB8QF8VoIsMgrcY1wYseJj4AWVUhwWiRukR_jBaQmpZT_z0xcSouQ9rLXOA9rvsTzjTPzDWNnIXjV6Crk4KLOkVJDbkoEJJbeh6hM7SqqHb6906N7dfNQPSy1-qKcsCQPnAx3LkqPL0lQyvpaRU18I8oghbEyuiKkMt-iWgqmhjUYWTOSi1SQV2PIcj4BmFL6jhh6rHy6oEGp_zt6-TVLcsntXG-zrTlf5BdpnjtsDbpdtnE7_yO-x16SbjSZl9sucL8QYE71lbyPfHzhuC5Ghtu_9gnpIH9GZ5b2ALkNj0AbZnyc-uRCbjntzfJJj2x6hvekXIJxP-VUAUGNJvbZ_fXvP1ejfN5GIfforWe5kYV1zoHWjTbeCrQjFJrqc3Soa1KIR5cfhW6cixY0BRhCSovjrib9evmDrXd9B4eMF86UsdEAgF7dGzxXa4GXOBUlWFFl7OzDsu0kqWW0GGUQAO0AQDsAkLFLsvriFJK4Hg4g8O0c-PZfwGfs1wdmLX4S9J_DdtC_vbalwbmTSo7I2EHCcPEo2WBEiGtqxpoVdFfmsjrSPT0OstsFRsJKS3H0P2Z_zDZLpEeUzVaoE7Y-m77BT6Q3M3c6vMnv2WH7EQ priority: 102 providerName: Directory of Open Access Journals |
Title | Generation and characterization of mAb 61H9 against junctional adhesion molecule-a with potent antitumor activity |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38495763 https://search.proquest.com/docview/2967056450 https://pubmed.ncbi.nlm.nih.gov/PMC10944630 https://doaj.org/article/02c196d44ac74f61932f3d309a3fb1d8 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCbaDhh2GfZe9gg0oFc3sqXI1rEt2gUDUhTDCuRm6NlmmO0sS___SDnOmmGnXXywHiZEWfwokZ8Ajr13slJTnwUbVYaQOmS6QIXEwjkfpS7tlHKH51dqdiO_LKaLA1BDLkwK2nd2edL-aE7a5V2KrVw1bjLEiU2u5-c5-iRSCT45hMNSiAc-elp_ETEjsOiT8Up0VyarENYUusPT_Sp_zE9i6f8XtPw7QvKBybl8Bk-3WJGd9jI9h4PQvoDH8-1p-Ev42XNG09Ay03rmduTLfW4l6yJrTi1T-Uwzc2uWCAXZdzRk_f4fM_4u0GYZa_o7ckNmGO3LslWHSHqDfVIcQdOtGWU_0CUTr-Dm8uLb-SzbXqGQObTUm0yL3Fhrg1KV0s5wV8qQK8rNUb4siR0ezX3kqrI2mqDIueBCGCy3JXHXi9dw1HZteAsst7qIlQohoEV3GusqxbGJlVEEw6cjOB5Gtl71TBk1ehikgDopoE4KGMEZjfquCtFbpxfd-rbeKrnmhcOVwUtpUOCoCGRG4QXXRkSbe-zk06CzGn8HOuMwbejuf9WFRtmJIYeP4E2vw92nRIXeIK6nI6j2tLsny34JzsBEuT3MuHf_3_Q9PCkQEFH8Wi4_wNFmfR8-IqDZ2DE8Oru4uv46ThsC-Py8yMdpTv8Gysz-AA |
link.rule.ids | 230,315,733,786,790,870,891,2115,27957,27958,33780,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lc9MwEN4pZQZ6oTxLaAEx06sT2XJk-1g67QRoOhzaoTePnm0A2yE4F349u3Icmg4XuFoPy96V9K20-y3AobUmzeXYRk57GSGkdlGRoEB8Yoz1aZHpMcUOT8_l5DL9eDW-2gLZx8IEp32jZ8P6ezWsZzfBt3JemVHvJzb6PD2O0SZJpeCje3AfJ2yS3bLSwwqMmBmhRReOl6HBMpo7tyDnHR4yrPzZgAJP_9_A5V0fyVubzukufOmH2_mafBsuWz00v-4wOf779zyGRyscyo668iew5eqn8GC6uml_Bj86PmoSG1O1ZWZN7NzFbbLGs-pIMxlPCqau1QxhJvuKm2R3tsiUvXF0EMeqLv-uixSjM182bxClt9gn-ShUzYJRZAUlsHgOl6cnF8eTaJWeITKIAtqoELHSWjspc1kYxU2WulhS3I-0WUbM8wglPJe51l45SYYLF0Jhuc6IF1-8gO26qd1LYLEuEp9L5xyiBVNgXSk5NtGpF07x8QAOe5mV846Fo0TrhURbBtGWQbQDeE_yXFch6uzwoFlcl6sfXvLE4Kpj01ThgL0kAOuFFbxQwuvYYifvem0ocarR_YmqXbP8WSYFjp3Yd_gA9jrtWL9K5Ghp4lo9gHxDbzbGslmC2hDovHvpv_r_pm_h4eRielaefTj_tA87CQIv8pOL0wPYbhdL9xqBU6vfhFnyG56RHLM |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXaFAh66b64KwvkKosSaUo8pmkNd3GQQwME6EHgmritljrypV_fGS1uHPSUq0hJlGZIviHfPBJy4JwVuZy5yJsgI4DUPlIpGCSk1rogVGZmmDu8PJaLU_H5bHY2sCovB1plZc1qWv0qp9XqouNWNqWNR55YfLI8SiAmEZKzuHEhvk3uQKdN1ZVIvRuFATcDvOhT8jIIWuLG-zUSeFh3ysq_SajT6v8fwLzOk7wy8czvk-9jk3u-yc_ppjVT--eamuPNvukBuTfgUXrY13lIbvnqEdlfDjvuj8nvXpcazUd15ajdCjz3-Zu0DrQ8NFQmC0X1uV4B3KQ_YLLs1xipdhceF-Ro2Z_D6yNNce2XNjWg9RaeiVyFsl5TzLDAgyyekNP5x29Hi2g4piGygAbaSPFEG2O8lLlUVjObCZ9IzP-RLstQgR4gRWAyNyZoLzGAYZxrKDcZ6uPzp2Svqiv_nNDEqDTk0nsPqMEqqCslg1uMCNxrNpuQg9FuRdOrcRQQxaB5i868RWfeCXmPNt1WQQnt7kK9Pi-Gn16w1MLo44TQ0OAgEcgG7jhTmgeTOHjIu9EjCuhyuI-iK19vLotUQdtRhYdNyLPeQ7av4jlEnDBmT0i-4zs7bdktAY_oZL1HD3hx81vfkv2TD_Pi66fjLy_J3RTwF9LlEvGK7LXrjX8N-Kk1b7qO8hdxZB8z |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Generation+and+characterization+of+mAb+61H9+against+junctional+adhesion+molecule-a+with+potent+antitumor+activity&rft.jtitle=PeerJ+%28San+Francisco%2C+CA%29&rft.au=Liu%2C+Kang&rft.au=Yang%2C+Hang&rft.au=Xiong%2C+Rong&rft.au=Shen%2C+Yunlong&rft.date=2024-03-14&rft.eissn=2167-8359&rft.volume=12&rft.spage=e17088&rft_id=info:doi/10.7717%2Fpeerj.17088&rft_id=info%3Apmid%2F38495763&rft.externalDocID=38495763 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2167-8359&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2167-8359&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2167-8359&client=summon |